AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
The FDA has prioritized reviewing Padcev and Keytruda for MIBC patients ineligible for cisplatin chemotherapy, with a target action date of April 7, 2026. Phase 3 EV-303 trial results showed a 60% ...
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes compared with standard of care (SoC) ...
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...
Zacks Investment Research on MSN
Will Keytruda continue to aid MRK's growth in 2026 after a strong Q1?
Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...
The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) blockbuster anti-PD-1 therapy Keytruda for bladder cancer as part of a combination ...
Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results